Aguilar-Salinas CA, Tussié-Luna T, Almeda-Valdés P

Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 209-210
Archivo PDF: 53.14 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jeff JM, Peloso GM, Do R. What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants? Curr Opin Lipidol. 2016;27:99-104.

2. Ellis KL, Hooper AJ, Burnett JR, Watts GF. Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nat Rev Endocrinol. 2016;12:467-84.

3. Danchin N, Almahmeed W, Al-Rasadi K, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The international choLesterol management practice study (ICLPS). Eur J Prev Cardiol. 2018;25:1087-94.

4. Ripatti P, Rämö JT, Söderlund S, et al. The Contribution of GWAS loci in familial dyslipidemias. PLoS Genet. 2016;12:e1006078.

5. Singh SA, Andraski AB, Pieper B, et al. Multiple apolipoprotein kinetics measured in human HDL by high-resolution/accurate mass parallel reaction monitoring. J Lipid Res. 2016;57:714-28.

6. Chait A, Goldberg I. Treatment of dyslipidemia in diabetes: recent advances and remaining questions. Curr Diab Rep. 2017;17:112.

7. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2:655-66.